Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 29, 2008, Pages 4739-4745

  Hershman, Dawn L ^a   McMahon, Donald J ^a   Crew, Katherine D ^a   Cremers, Serge ^a   Irani, Dinaz ^a   Cucchiara, Gina ^a   Brafman, Lois ^a   Shane, Elizabeth ^a  

^a NewYork Presbyterian Hospital

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EYE DISCOMFORT; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INSOMNIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MUSCLE STIFFNESS; MYALGIA; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; OSTEOPOROSIS; PREMENOPAUSE;

EID: 54249151531     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.4707     Document Type: Article

References (29)

1. Hewitt M, Breen N, Devesa S: Cancer prevalence and survivorship issues: Analyses of the 1992 National Health Interview Survey. J Natl Cancer Inst 91:1480-1486, 1999
2. Wingo PA, Ries LA, Parker SL, et al: Longterm cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 7:271-282, 1998
3. Edwards BK, Brown ML, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427, 2005
4. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996
5. Kanis JA, McCloskey EV, Powles T, et al: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181, 1999
6. Bruning PF, Pit MJ, de Jong-Bakker M, et al: Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308-310, 1990
7. Headley JA, Theriault RL, LeBlanc AD, et al: Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16:6-11, 1998
8. Fuleihan Gel-H, Salamoun M, Mourad YA, et al: Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial. J Clin Endocrinol Metab 90:3209-3214, 2005
9. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with earlystage breast cancer. J Clin Oncol 19:3306-3311, 2001
10. Chen Z, Maricic M, Bassford TL, et al: Fracture risk among breast cancer survivors: Results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558, 2005
11. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate,andfluorouracilchemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997
12. Saarto T, Blomqvist C, Valimaki M, et al: Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75:602-605, 1997
13. Bonnick S, Saag KG, Kiel DP, et al: Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631-2637, 2006
14. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820-828, 2007
15. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997
16. Greenspan SL, Bhattacharya RK, Sereika SM, et al: Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 92:131-136, 2007
17. Powles TJ, McCloskey E, Paterson AH, et al: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708, 1998
18. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
19. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005
20. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al: Bone mineral density at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid. 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr)
21. Black DM, Delmas PD, Eastell R, et al: Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822, 2007
22. Reid IR, Miller P, Lyles K, et al: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898-908, 2005
23. Garnero P, Hausherr E, Chapuy MC, et al: Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538, 1996
24. Hui SL, Slemenda CW, Johnston CC Jr: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804-1809, 1988
25. Hans D, Downs RW Jr, Duboeuf F, et al: Skeletal sites for osteoporosis diagnosis: The 2005 ISCD Official Positions. J Clin Densitom 9:15-21, 2006
26. Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report - WHO Study Group. Osteoporos Int 4:368-381, 1994
27. Fogelman I, Blake GM, Blamey R, et al: Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14:1001-1006, 2003
28. Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259, 1996
29. Gralow JR: Bone density in breast cancer: When to intervene? J Clin Oncol 25:3194-3197, 2007